A Phase 1 interventional study of YF087 in Advanced Solid Tumor Cancer, sponsored by InventisBio Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Treatment
This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid tumors.
Exclusion Criteria:
Use of, or planned use of, any of the following medications that has not been discontinued for at least 14 days or 5 half-lives (whichever is shorter) before the first study drug administration:
Drug: YF087
Dosage form: Tablet • Administration route: Oral, once a day
Number of subjects participants with adverse events
Number of subjects participants with adverse events
Time frame: From enrollment to 30 days after last dose
Subject incidence of Dose-limiting toxicities (DLT)
Time frame: From enrollment to Cycle 1 Day 21
Objective response rate (ORR)
Time frame: From enrollment to the end of treatment, about 1 year
Disease control rate (DCR)-assessed by IRC and investigators
Time frame: From enrollment to the end of treatment, about 1 year
Progression free survival (PFS)
Time frame: From enrollment to the end of treatment, about 1 year
Duration of Response (DOR)
Time frame: From enrollment to the end of treatment, about 1 year
Change from baseline in QT/QTc interval
Time frame: On Cycle 0 Day 1 and Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: area under the concentration-time curve from the time of dosing to time t (AUC0-t)
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: area under the concentration-time curve from time 0 to infinity (AUC0-∞)
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: Mean residence time (MRT)
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: maximum concentration (Cmax)
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: Time to maximum concentration (Tmax)
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: t1/2
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Primary PK parameters: Apparent Volume of Distribution (Vz/F)
Time frame: From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)
Change from baseline in concentration and/or mutations in ctDNA
Time frame: From enrollment to the end of treatment, about 1 year
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InventisBio Co., Ltd